Semin Thromb Hemost 2009; 35(2): 181-188
DOI: 10.1055/s-0029-1220326
© Thieme Medical Publishers

Diagnostic Evaluation of Platelet Function Disorders in Neonates and Children: An Update

Sara J. Israels1 , 2 , 3
  • 1Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada
  • 2The Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, Manitoba, Canada
  • 3Haemostasis Laboratory, Health Sciences Centre, Winnipeg, Manitoba, Canada
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
30. April 2009 (online)

ABSTRACT

Investigation of platelet function disorders in infants and small children requires the collaborative efforts of clinicians and clinical laboratories. A detailed personal, family, and medication history, and a search for additional clinical phenomena may help to direct diagnostic laboratory investigations. Testing for these disorders in young children presents several challenges: the requirement of relatively large volumes of blood, lack of standardization, and the absence of well-established age-specific reference ranges. Neonates show the most notable differences in platelet function compared to older children and adults; the decreased platelet activation responses persist for the first 2 to 4 weeks after delivery. Small studies of normal postneonatal pediatric populations have provided data on platelet function assays, including bleeding times, PFA-100 closure times, thromboelastography, aggregation, secretion, and flow cytometry. The majority of these studies, comparing normal children with adults, found only minor differences in platelet responses measured by these assays.

REFERENCES

  • 1 Khair K, Liesner R. Bruising and bleeding in infants and children – a practical approach.  Br J Haematol. 2006;  133 221-231
  • 2 Nosek-Cenkowska B, Cheang M S, Pizzi N J, Israels E D, Gerrard J M. Bruising/bleeding symptomatology in children with and without bleeding disorders.  Thromb Haemost. 1991;  65 237-241
  • 3 Katsanis E, Luki K-H, Hsu E, Li M, Lillicrap D. Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis.  J Pediatr. 1988;  113 73-76
  • 4 Hedlund-Treutiger I, Revel-Vilk S, Blanchette V S, Curtin J A, Lillicrap D, Rand M L. Reliability and reproducibility of classification of children as “bleeders” versus “non-bleeders” using a questionnaire for significant mucocutaneous bleeding.  J Pediatr Hematol Oncol. 2004;  26 488-491
  • 5 Biss T T, Blanchette V, Bowman M et al.. Quantitation of bleeding symptoms in children with von Willebrand disease (VWD) or a platelet function disorder: use of a standardized pediatric bleeding score.  Blood. 2007;  110 2137 [abstract]
  • 6 Israels S J, Daniels M, McMillan E M. Deficient collagen-induced activation in the newborn platelet.  Pediatr Res. 1990;  27 337-343
  • 7 Israels S J, Odaibo F S, Robertson C, McMillan E M, McNicol A. Deficient thromboxane synthesis and response in platelets from premature infants.  Pediatr Res. 1997;  41 218-223
  • 8 Rajasekhar D, Kestin A S, Bednarek F J, Ellis P A, Barnard M R, Michelson A D. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood.  Thromb Haemost. 1994;  72 957-963
  • 9 Rajasekhar D, Barnard M R, Bednarek F J, Michelson A D. Platelet hyporeactivity in very low birth weight neonates.  Thromb Haemost. 1997;  77 1002-1007
  • 10 Andrew M, Paes B, Bowker J, Vegh P. Evaluation of an automated bleeding time device in the newborn.  Am J Hematol. 1990;  35 275-277
  • 11 Carcao M D, Blanchette V S, Dean J A et al.. The platelet function analyzer (PFA-100®): a novel in vitro system for evaluation of primary haemostasis in children.  Br J Haematol. 1998;  101 70-73
  • 12 Israels S J, Cheang T, McMillan-Ward E M, Cheang M. Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyzer.  J Pediatr. 2001;  138 116-119
  • 13 Roschitz B, Sudi K, Kostenberger M, Muntean W. Shorter PFA-100 closure times in neonates than in adults: role of red cells, white cells, platelets and von Willebrand factor.  Acta Paediatr. 2001;  90 664-670
  • 14 Stuart M J, Allen J B. Arachidonic acid metabolism in the neonatal platelet.  Pediatrics. 1982;  69 714-718
  • 15 Israels S J, Cheang T, Robertson C, McMillan-Ward E M, McNicol A. Impaired signal transduction in neonatal platelets.  Pediatr Res. 1999;  45 687-691
  • 16 Gelman B, Setty B NY, Chen D, Amin-Hanjani S A, Stuart M J. Impaired mobilization of intracellular calcium in neonatal platelets.  Pediatr Res. 1996;  39 692-696
  • 17 Michelson A D. Platelet function in the newborn.  Semin Thromb Hemost. 1998;  24 507-512
  • 18 Gatti L, Guarneri D, Caccamo M L, Gianotti G A, Marini A. Platelet activation in newborns detected by flow-cytometry.  Biol Neonate. 1996;  70 322-327
  • 19 Ucar T, Gurman C, Arsan S, Kemahli S. Platelet aggregation in term and preterm newborns.  Pediatr Hematol Oncol. 2005;  22 139-145
  • 20 Sitaru A G, Holzhauer S, Speer C P et al.. Neonatal platelets from cord blood and peripheral blood.  Platelets. 2005;  16 203-210
  • 21 Hezard N, Potron G, Schlegel N, Amory C, Leroux B, Nguyen P. Unexpected persistence of platelet hyporeactivity beyond the neonatal period: a flow cytometric study in neonates, infants and older children.  Thromb Haemost. 2003;  90 116-123
  • 22 Ichinose F, Uezono S, Muto R et al.. Platelet hyporeactivity in young infants during cardiopulmonary bypass.  Anesth Analg. 1999;  88 258-262
  • 23 Patrick C H, Lazarchick J, Stubbs T, Pittard W B. Mean platelet volume and platelet distribution width in the neonate.  Am J Pediatr Hematol Oncol. 1987;  9 130-132
  • 24 Forestier F, Daffos F, Galacteros F, Bardakjian J, Rainaut M, Beuzard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation.  Pediatr Res. 1986;  20 342-346
  • 25 Kipper S L, Sieger L. Whole blood platelet volumes in newborn infants.  J Pediatr. 1982;  101 763-766
  • 26 Arad I D, Alpan G, Sznajderman S D, Eldor A. The mean platelet volume (MPV) in the neonatal period.  Am J Perinatol. 1986;  3 1-3
  • 27 Witkop C J, Krumwiede M, Sedano H, White J G. Reliability of absent platelet dense bodies as a diagnostic criterion for Hermansky-Pudlak syndrome.  Am J Hematol. 1987;  26 305-311
  • 28 White J G, Krumwiede M. Some contributions of electron microscopy to knowledge of human platelets.  Thromb Haemost. 2007;  98 69-72
  • 29 Saving K, Aldag J, Jennings D, Caughey B, Regan M, Powers W. Electron microscopic characterization of neonatal platelet ultrastructure: effects of sampling techniques.  Thromb Res. 1991;  61 65-80
  • 30 Andrew M, Castle V, Mitchell L, Paes B. Modified bleeding time in the infant.  Am J Hematol. 1989;  30 190-191
  • 31 Andrew M, Paes B, Bowker J, Vegh P. Evaluation of an automated bleeding time device in the newborn.  Am J Hematol. 1990;  35 275-277
  • 32 Del Vecchio A. Use of the bleeding time in the neonatal intensive care unit.  Acta Paediatr Suppl. 2002;  91 82-86
  • 33 Del Vecchio A, Ltina G, Henry E, Christensen R D. Template bleeding times of 240 neonates born at 24 to 41 weeks gestation.  J Perinatol. 2008;  28 427-431
  • 34 Katz J A, Moake J L, McPherson P D et al.. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma.  Blood. 1989;  73 1851-1858
  • 35 Weinstein M J, Blanchard R, Moake J L, Vosburgh E, Moise K. Fetal and neonatal von Willebrand factor(vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 1989;  72 68-72
  • 36 Gerrard J M, Docherty J C, Israels S J et al.. A reassessment of the bleeding time: association of age, hematocrit, platelet function, von Willebrand factor, and bleeding time thromboxane B2 with the length of the bleeding time.  Clin Invest Med. 1989;  12 165-171
  • 37 Sola M C, del Vecchio A, Edwards T J, Suttner D, Hutson A D, Christensen R D. The relationship between hematocrit and bleeding time in very low birth weight infants during the first week of life.  J Perinatol. 2001;  21 368-371
  • 38 Kundu S K, Heilmann E J, Sio R, Garcia C, Ostgaard R A. Characterization of an in vitro platelet function analyzer, PFA-100® .  Clin Appl Thromb Hemost. 1996;  2 241-249
  • 39 Favaloro E J, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100™) with a high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders.  Am J Hematol. 1999;  62 165-174
  • 40 Fressinaud E, Veyradier A, Truchaud F et al.. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.  Blood. 1998;  91 1325-1331
  • 41 Israels S J, Cheang T, McMillan-Ward E M, Houston D. Comparison of the PFA-100® platelet function analyzer and the template bleeding time in evaluation of patients with a clinical bleeding history.  Blood. 1999;  94(Suppl 1) 452 [abstract]
  • 42 Carcao M D, Blanchette V S, Dean J A et al.. The platelet function analyzer (PFA-100®): a novel in vitro system for evaluation of primary haemostasis in children.  Br J Haematol. 1998;  101 70-73
  • 43 Roschitz B, Sudi K, Kostenberger M, Muntean W. Shorter PFA-100 closure times in neonates than in adults: role of red cells, white cells, platelets and von Willebrand factor.  Acta Paediatr. 2001;  90 664-670
  • 44 Boudewijns M, Raes M, Peeters V et al.. Evaluation of platelet function on cord blood in 80 healthy term neonates using the platelet function analyser (PFA-100): shorter in vitro bleeding times in neonates than adults.  Eur J Pediatr. 2003;  162 212-213
  • 45 Lippi G, Manzato F, Franchini M, Brocco G, Florenziani G, Guidi G. Establishment of reference values for the PFA-100 platelet function analyzer in pediatrics.  Clin Exp Med. 2001;  1 69-70
  • 46 Perel J M, Just S, Rowell J, Williams B, Kennedy G A. Utility of the PFA-100 analyser in the evaluation of primary haemostasis in a paediatric population.  Int J Lab Hematol. 2007;  29 480-481
  • 47 Hayward C PM, Harrison P, Cattaneo M, Ortel T L, Rao A K. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function.  J Thromb Haemost. 2006;  4 312-319
  • 48 Roschitz B, Thaller S, Koestenberger M et al.. PFA-100 closure times in preoperative screening in 500 pediatric patients.  Thromb Haemost. 2007;  98 243-247
  • 49 Harrison P. The role of PFA-100® testing in the investigation and management of haemostatic defects in children and adults.  Br J Haematol. 2005;  130 3-10
  • 50 Cariappa R, Wilhite T R, Parvin C A, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems.  J Pediatr Hematol Oncol. 2003;  25 474-479
  • 51 Hanebutt F L, Rolf N, Loesel A, Kuhlisch E, Siegert G, Knoefler R. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.  Haemophilia. 2008;  14 524-530
  • 52 Pivalizza E G, Pivalizza P J, Gottschalk L I, Kee S, Szmuk P, Abramson D C. Celite-activated thromboelastography in children.  J Clin Anesth. 2001;  13 20-23
  • 53 Rajwal S, Richards M, O'Meara M. The use of recalcified citrated whole blood—a pragmatic approach for thromboelastography in children.  Paediatr Anaesth. 2004;  14 656-660
  • 54 Yee D L, Edwards R M, Mueller B U, Teruya J. Thromboelastographic and hemostatic characteristics in pediatric patients with sickle cell disease.  Arch Pathol Lab Med. 2005;  129 760-765
  • 55 Chan K L, Summerhayes R G, Ignajavtovic V, Horton S B, Monagle P T. Reference values for kaolin-activated thromboelastography in healthy children.  Anesth Analg. 2007;  105 1610-1613
  • 56 Miller B E, Bailey J M, Mancuso T J et al.. Functional maturity of the coagulation system in children: an evaluation using thrombelastography.  Anesth Analg. 1997;  84 745-748
  • 57 Kettner S C, Pollak A, Zimpfer M et al.. Heparinase-modified thrombelastography in term and preterm neonates.  Anesth Analg. 2004;  98 1650-1652
  • 58 Varon D, Dardik R, Shenkman B et al.. A new method for quantitative analysis of whole blood platelet interaction with the extracellular matrix under flow conditions.  Thromb Res. 1997;  85 283-294
  • 59 Levy-Shraga Y, Maayan-Metzber A, Lubtsky A et al.. Platelet function of newborns as tested by cone and plate(let) analyzer correlates with gestational age.  Acta Haematol. 2006;  115 152-156
  • 60 Shenkman B, Linder N, Savion N et al.. Increased neonatal platelet deposition on subendothelium under flow conditions: the role of plasma von Willebrand factor.  Pediatr Res. 1999;  45 270-275
  • 61 Linder N, Shenkman B, Levin E et al.. Deposition of whole blood platelets on extracellular matrix under flow conditions in preterm infants.  Arch Dis Child Fetal Neonatal Ed. 2002;  86 F127-F130
  • 62 Mull M M, Hathaway W E. Altered platelet function in newborns.  Pediatr Res. 1970;  4 229-237
  • 63 Ts'ao C H, Green D, Schultz K. Function and ultrastructure of platelets of neonates: enhanced ristocetin aggregation of neonatal platelets.  Br J Haematol. 1976;  32 225-233
  • 64 Corby D G, O'Barr T P. Neonatal platelet function: a membrane-related phenomenon?.  Haemostasis. 1981;  10 177-185
  • 65 Corby D G, O'Barr T P. Decreased alpha-adrenergic receptors in newborn platelets: cause of abnormal response to epinephrine.  Dev Pharmacol Ther. 1981;  2 215-225
  • 66 Israels S J, Andrew M. Neonatal hemostasis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD Haemostasis and Thrombosis, 3rd ed. Edinburgh, United Kingdom; Churchill Livingstone 1994: 1017-1055
  • 67 Johnson S S, Montgomery R R, Hathaway W E. Newborn factor VIII complex: elevated activities in term infants and alterations in electrophoretic mobility related to illness and activated coagulation.  Br J Haematol. 1981;  47 597-606
  • 68 Bonduel M, Frontroth J P, Hepner M, Sciuccati G, Feliu-Torres A. Platelet aggregation and adenosine triphosphate release values in children and adults.  J Thromb Haemost. 2007;  5 1782-1787
  • 69 Kuhne T, Ryan G, Blanchette V et al.. Platelet-surface glycoproteins in healthy and preeclamptic mothers and their newborn infants.  Pediatr Res. 1996;  40 876-880
  • 70 Gunay-Aygun M, Huizing M, Gahl W A. Molecular defects that affect platelet dense granules.  Semin Thromb Hemost. 2004;  30 537-547
  • 71 Nurden P, Nurden A T. Congenital disorders associated with platelet dysfunctions.  Thromb Haemost. 2008;  99 253-263
  • 72 Walker M, Payne J, Wagner B, Vora A. Hermansky-Pudlak syndrome.  Br J Haematol. 2007;  138 671
  • 73 Hayward C P. Diagnostic approach to platelet function disorders.  Transfus Apher Sci. 2008;  38 65-76
  • 74 Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.  Paediatr Drugs. 2001;  3 817-858
  • 75 Acharya S, Bussel J B. Hematologic toxicity of sodium valproate.  J Pediatr Hematol Oncol. 2000;  22 62-65
  • 76 Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle C E. High incidence of valproate-induced coagulation disorders in children receiving valproic acid: a prospective study.  Blood Coagul Fibrinolysis. 2008;  19 375-382
  • 77 Halperin D, Reber G. Influence of anti-depressants on hemostasis.  Dialogues Clin Neurosci. 2007;  9 47-59
  • 78 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure.  Semin Thromb Hemost. 2004;  30 579-589
  • 79 Gerrard J M, McNicol A. Platelet storage pool deficiency, leukemia, and myelodysplastic syndromes.  Leuk Lymphoma. 1992;  8 277-281
  • 80 Manoharan A, Brighton T, Gemmell R, Lopez K, Moran S, Kyle P. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study.  Int J Hematol. 2002;  76 272-278
  • 81 Gurbel P A, Becker R C, Mann K G, Steinhubl S R, Michelson A D. Platelet function monitoring in patients with coronary artery disease.  J Am Coll Cardiol. 2007;  50 1822-1834
  • 82 Yee D L, Dinu B R, Sun C W et al.. Low prevalence and assay discordance of “aspirin resistance” in children.  Pediatr Blood Cancer. 2008;  51 86-92
  • 83 Li J S, Yow E, Berezny K Y et al.. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.  Circulation. 2008;  117 553-559

Dr. Sara J Israels

Pediatric Hematology/Oncology, CancerCare Manitoba

675 McDermot Ave., Winnipeg, Manitoba, Canada, R3E 0V9

eMail: israels@cc.umanitoba.ca